Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy

October 19th, 2004

Clinical Trials of New Nanoengineered Therapeutic for Chemotherapy

Abstract:
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that Insert is planning with City of Hope Comprehensive Cancer Center a broad-based Phase I clinical trial for Insert's lead drug candidate.

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Arrowhead Research Corporation

Related News Press

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

Quantum twisted Loong confirms the physical reality of wavefunctions September 23rd, 2017

Application of air-sensitive semiconductors in nanoelectronics: 2-D semiconductor gallium selenide in encapsulated nanoelectronic devices September 22nd, 2017

Researchers set time limit for ultrafast perovskite solar cells September 22nd, 2017

DNA triggers shape-shifting in hydrogels, opening a new way to make 'soft robots' September 21st, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project